Diabetes & Obesity Series
Subscribe to RSS feed of this series
Dr. Richard Gregg
Chief Scientific Officer
Vitae Pharmaceuticals
Dr. Gregg offers insight into the development of obesity drugs, and how co-morbidities factor into development, as well as how it impacts sites and CROs in Phase I through III trials.
Others in the Series
Associations and Societies
Clinical Trials
Articles, Multimedia
Associations and Societies
Clinical Trials
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.